How does the operation of PHARMAC's 'Community Exceptional ...

More documents

Recommendations

Info

Cullen, M., & Mallard, T. (2006). Improving performance and value for money within and across votes Report to Cabinet Policy Committee. Wellington: NZ Government. Cumming, J., Mays, N., & Daube, J. (2010). How New Zealand has contained expenditure on drugs. British Medical Journal, 340 (May 18 1), c2441. doi: 10.1136/bmj.c2441 Cumming, J., Powell, M., & Barnett, P. (2004). Governance in District Health Boards in New Zealand: A report on progress Public Sector, Vol.27((2)), p4-9. Daniels, N. (2008). Just Health. New York Cambridge University Press p89. Daniels, N., & Sabin, J. (1998). The Ethics of Accountability in Managed Care Reform. Health Affairs, 17(5), 50. Daniels, N., & Sabin, J. (2008). Setting Limits Fairly ; Learning to Share Resources for Health. New York Oxford University Press. p67. Davidson, J., & Jacobs, C. (2008). The Implications of Qualitative Research Software for Doctoral Work. Qualitative Research Journal, 8(2), 72-80. Davis, K., Schoen, C., & Stremikis, K. (2010). Mirror, Mirror on the wall. How the Performance of the U.S. Health Care System Compares Internationally 2010 Update (Vol. 1). London: The Commonwealth Fund. Deane, R. (2000). Globalisation and Constitutional Development. In C. James (Ed.), Building the Constitution (Vol. 1). Wellington: Institute of Public Policy (p112). Denzin, K., & Lincoln Y.S. (2002) The Qualitative Inquiry Reader. Sage Publications, London, New Delhi p229-230. 290
Dew, K., Cumming, J., McLeod, D., Morgan, S., McKinlay, E., Dowell, A., & Love, T. (2005). Explicit rationing of elective services: implimenting the New Zealand reforms. Health Policy, 74, 1-12. doi: 10.1016/j.healthpol.2004.12.011 Dixon, J., & New, B. (1997). Setting Priorities NZ-Style, Can we learn from it? . [Letter to the Editor]. British Medical Journal, 314, 131-135. Dow, D. (1995). Safeguarding the public Health: A History of the New Zealand Department of Health (Vol. 1). Wellington: Victoria University Press p121. Drummond, M. (2009). Rationing new medicines in the UK. British Medical Journal, 338 (a3182). doi: 10.1136/bmj.a3182 Dworkin, R. (1981). What is equality? Part 1: Equality of Resources. Philosophy and Public Affairs(10), p186. Edgar, W. (2000). Rationing in Health Care - A New Zealand Perspective on an International Dilemma Bollettinodei medici svizzeri, 41(Nr4). Retrieved from http://www.saez.ch/pdf/2000/2000-04/2000-04-1375.pdf on 30.06.2010 Edlin, R., Round, R., Hulme, C., & McCabe, C. (2010). Cost-effectiveness analysis and efficient use of the pharmaceutical budget: the key role of clinical pharmacologists. The British Pharmacological Society, Article first published online: 21.01.10. doi: 10.1111/j.1365-2125.2010.03617.x English, B. (2011). Budget Speech 2011. Wellington: The Treasury Retrieved from http://www.treasury.govt.nz/budget/2011/speech accessed on 31.07.2011. Ernts E. (2006). New Zealanders’ love affair with “alternative” medicine: reason for concern? New Zealand Medical Journal, 119 (1233 ). 291
Page 1 and 2:
How does the operation of PHARMAC
Page 3 and 4:
Applying the Test-Questions .......
Page 5 and 6:
Appendix 9: Analysis of Material Re
Page 7 and 8:
List of Abbreviations ABS Australia
Page 9 and 10:
Attestation of Authorship I hereby
Page 11 and 12:
I gratefully acknowledge Major Camp
Page 13 and 14:
Abstract This thesis explores how g
Page 15 and 16:
Chapter 1: Introduction What is thi
Page 17 and 18:
making? Should a person’s level o
Page 19 and 20:
there is no mathematical calculatio
Page 21 and 22:
health, disability, treatment of ol
Page 23 and 24:
I then moved to the subject of rati
Page 25 and 26:
In Chapter 3, New Zealand’s past
Page 27 and 28:
Chapter 2: Background Introduction
Page 29 and 30:
The following journals have no auto
Page 31 and 32:
Technological and pharmaceutical di
Page 33 and 34:
in every sense, and attenuates the
Page 35 and 36:
waiting time for first (or subseque
Page 37 and 38:
Macro-Level Distributions Macro-lev
Page 39 and 40:
(2000) in a report for the Ministry
Page 41 and 42:
level, too many to discuss here. On
Page 43 and 44:
effectiveness of treatment. However
Page 45 and 46:
surgical treatment for ectopic preg
Page 47 and 48:
In a study conducted by the Commonw
Page 49 and 50:
They claim that health inequities c
Page 51 and 52:
these presentations are correct, th
Page 53 and 54:
waiting list for patient priority.
Page 55 and 56:
care within finite resources. The c
Page 57 and 58:
to pay for this co-operation. In 20
Page 59 and 60:
Other results showed that 81% of th
Page 61 and 62:
may be grounds for litigation. Henc
Page 63 and 64:
determine if decisions on the appli
Page 65 and 66:
Chapter 4: Philosophical Framework
Page 67 and 68:
extra person with a good or service
Page 69 and 70:
just actions by individuals. The th
Page 71 and 72:
among the members of the society, a
Page 73 and 74:
example of well off and powerful pe
Page 75 and 76:
necessarily much advantaged over a
Page 77 and 78:
among individuals and communities.
Page 79 and 80:
needs. This was because distinguish
Page 81 and 82:
systematic and transparent. In her
Page 83 and 84:
why PHARMAC would subsidise unecono
Page 85 and 86:
parents refusing treatment for thei
Page 87 and 88:
The first two test-questions covere
Page 89 and 90:
There was no clarity provided by th
Page 91 and 92:
good may be served by their not rec
Page 93 and 94:
Evans (2003) ranked the various typ
Page 95 and 96:
The Use of the Test-Questions in Th
Page 97 and 98:
Qualitative research methods were d
Page 99 and 100:
equirements and considerable politi
Page 101 and 102:
material and by working through the
Page 103 and 104:
and printed copies of Hansard are a
Page 105 and 106:
PHARMAC was criticised in 16 of the
Page 107 and 108:
I tried to find an interviewee from
Page 109 and 110:
The flow of discussion in the inter
Page 111 and 112:
that the disclosure is commercially
Page 113 and 114:
6. Producing the report The final o
Page 115 and 116:
The following tables outline the no
Page 117 and 118:
Table 3: Tree Nodes Used in NVivo A
Page 119 and 120:
At this point, I stopped using NViv
Page 121 and 122:
Chapter 6: Research Findings Introd
Page 123 and 124:
DHBs were given the role of funding
Page 125 and 126:
These measures were in response to
Page 127 and 128:
Table 5: The Submitters to the Heal
Page 129 and 130:
towards New Zealand and for them to
Page 131 and 132:
monopolies as such. In their opinio
Page 133 and 134:
for the delivery of such services (
Page 135 and 136:
NCWNZ that S42(a) of the Bill, requ
Page 137 and 138:
contentious among Maori Iwi. Any Ma
Page 139 and 140:
Dugdale further advised that if non
Page 141 and 142:
cumbersome and recommended that PHA
Page 143 and 144:
following text, I have individually
Page 145 and 146:
Herceptin. The plaintiffs forwarded
Page 147 and 148:
the treatment of cancer in the DHB
Page 149 and 150:
eligible people in New Zealand and
Page 151 and 152:
confirmation that the DHB hospital
Page 153 and 154:
the eight women involved in this ca
Page 155 and 156:
the plaintiffs adequate opportunity
Page 157 and 158:
Judge’s Concluding Remarks The fi
Page 159 and 160:
A Selection of the Media Stories Ca
Page 161 and 162:
Case 4: “Worn out by endless figh
Page 163 and 164:
Case 6: “PHARMAC scolded for MS-d
Page 165 and 166:
The drug to treat Pompe’s Disease
Page 167 and 168:
The Voice of Patients and Family Me
Page 169 and 170:
Sclerosis Society did this three ti
Page 171 and 172:
was suffering would not pass the ra
Page 173 and 174:
Eight of the twelve persons approac
Page 175 and 176:
Part II: The Key Informant Intervie
Page 177 and 178:
agreed this was done. Secondly, PHA
Page 179 and 180:
the pharmaceutical schedule. The or
Page 181 and 182:
No we have never thought that $3 mi
Page 183 and 184:
Insights were given as to the indep
Page 185 and 186:
and Now some people can say that’
Page 187 and 188:
Q Be a voice for the family? A Yes,
Page 189 and 190:
key issue here. Some clinicians wer
Page 191 and 192:
I deeply suspect that Community Exc
Page 193 and 194:
should be developing the capacity o
Page 195 and 196:
make. And so PHARMAC has been a hug
Page 197 and 198:
and PHARMAC is not above rationing
Page 199 and 200:
This case demonstrated that the cos
Page 201 and 202:
and budget management. It says this
Page 203 and 204:
Q Do you recall the Kaletra issues
Page 205 and 206:
Q Can I ask you about PHARMAC’s c
Page 207 and 208:
….successfully…for things espec
Page 209 and 210:
This was also done for the hard cop
Page 211 and 212:
The Ministry of Health could not lo
Page 213 and 214:
consultation documents which relate
Page 215 and 216:
The following information was recei
Page 217 and 218:
with the application. The discharge
Page 219 and 220:
Again no report was attached from t
Page 221 and 222:
The patient was also prescribed pre
Page 223 and 224:
circumstances described were not su
Page 225 and 226:
treatment was not unusual and the c
Page 227 and 228:
their clinical circumstances would
Page 229 and 230:
Theme 1. Theme 2. Theme 3. Theme 4.
Page 231 and 232:
Chapter 7: Discussion Introduction
Page 233 and 234:
the intellectual property to recove
Page 235 and 236:
The use of QALY’s was tested in t
Page 237 and 238:
Test-Question 2 “Is this distribu
Page 239 and 240:
claimants (and unsuccessful drug co
Page 241 and 242:
(2011-2012) in an open and transpar
Page 243 and 244:
The cost-utility analysis system ha
Page 245 and 246:
Another form of decision making use
Page 247 and 248:
discuss how (or if) PHARMAC meets t
Page 249 and 250:
Test-question 4 also raises the pro
Page 251 and 252:
when there is no profound evidence
Page 253 and 254: for example value for money, equity
Page 255 and 256: Community Exceptional Circumstances
Page 257 and 258: Interferon available to a limited n
Page 259 and 260: challenges are multiple: to identif
Page 261 and 262: The data from the research showed h
Page 263 and 264: PHARMAC could be more open about st
Page 265 and 266: Chapter 8: Conclusions Introduction
Page 267 and 268: Limitations to the Research The ite
Page 269 and 270: There is no one set of indefeasible
Page 271 and 272: to alcohol and drug treatment or th
Page 273 and 274: well placed to lead further researc
Page 275 and 276: utilitarian principles of attemptin
Page 277 and 278: stand up to the same rigorous clini
Page 279 and 280: Appendices: Appendix 1: Ethics Appr
Page 281 and 282: Appendix 2: Key Informant Participa
Page 283 and 284: Appendix 3: Key Informant Consent F
Page 285 and 286: Appendix 4: Sample Interview Questi
Page 287 and 288: Appendix 5: OIA Request Greg Coyle
Page 289 and 290: Appendix 6: OIA Response from PHARM
Page 291 and 292: Appendix 7: Community Exceptional C
Page 293 and 294: 279
Page 295 and 296: 281
Page 297 and 298: 283
Page 299 and 300: Appendix 8: Community Exceptional C
Page 301 and 302: Ashton, T., & St John, S. (2008). N
Page 303: Cohen, G. A. (2008). Rescuing Justi
Page 307 and 308: Glubb, N. (2011). Official Informat
Page 309 and 310: Holt, S., Harwood, M., Aldington, S
Page 311 and 312: Lindblom, C. E. (1959). The Science
Page 313 and 314: http://www.moh.govt.nz/moh.nsf/ea60
Page 315 and 316: Cash Flows (Ed.), Government of New
Page 317 and 318: PB/132 National Council of Women of
Page 319 and 320: Romano, C. (2009). Amartya Sen Shak
Page 321 and 322: Swedish Parliamentary Priorities Co
show all

How does the operation of PHARMAC's 'Community Exceptional ...

Create successful ePaper yourself

Delete template?

Save as template?